Literature DB >> 34840111

Mechanistic roles of mutant p53 governing lipid metabolism.

Ryan M Loughran1, Brooke M Emerling2.   

Abstract

Metabolic reprogramming of cancer cells by various acquired mutations provides support for rapid proliferation and growth in the tumor microenvironment. Mutations in the TP53 gene are the most common mutation found across all human cancers. Commonly referred to as "the guardian of the genome", p53 has a well-established role as a tumor suppressor by mediating checkpoint integrity and protecting cells from DNA damage. To date, the many functional roles of p53 extending beyond its classical function and exerting control over metabolic processes continues to confound the field. Recently, emerging roles for p53 in mediating lipid metabolism have come to light with intriguing metabolic roles in regulating cholesterol homeostasis and lipid droplet formation. Herein, we will seek to unify the mechanisms by which absence of functional p53, as well as stable mutant forms of p53, exert control over these lipid metabolism programs. Of equal importance, synthetic lethal phenotypes in the context of mutant p53 and aberrant lipid homeostasis offer new possible targets in the therapeutic landscape. This review aims to characterize the mechanisms by which p53 exerts control over these pathways and examine how precision medicine may benefit from tumor subtyping of p53 mutations.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Cholesterol; Lipid droplet; Metabolism; Mevalonate; Synthetic lethality

Mesh:

Substances:

Year:  2021        PMID: 34840111      PMCID: PMC8858851          DOI: 10.1016/j.jbior.2021.100839

Source DB:  PubMed          Journal:  Adv Biol Regul        ISSN: 2212-4926


  77 in total

1.  Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport.

Authors:  Omer F Kuzu; Raghavendra Gowda; Arati Sharma; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2014-03-31       Impact factor: 6.261

2.  A transcriptionally active DNA-binding site for human p53 protein complexes.

Authors:  W D Funk; D T Pak; R H Karas; W E Wright; J W Shay
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

3.  Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER.

Authors:  Tong Yang; Peter J Espenshade; Michael E Wright; Daisuke Yabe; Yi Gong; Ruedi Aebersold; Joseph L Goldstein; Michael S Brown
Journal:  Cell       Date:  2002-08-23       Impact factor: 41.582

4.  Membrane-bound domain of HMG CoA reductase is required for sterol-enhanced degradation of the enzyme.

Authors:  G Gil; J R Faust; D J Chin; J L Goldstein; M S Brown
Journal:  Cell       Date:  1985-05       Impact factor: 41.582

5.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

Review 6.  The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling.

Authors:  Suneng Fu; Steven M Watkins; Gökhan S Hotamisligil
Journal:  Cell Metab       Date:  2012-05-02       Impact factor: 27.287

Review 7.  Metabolic regulation by p53.

Authors:  Oliver D K Maddocks; Karen H Vousden
Journal:  J Mol Med (Berl)       Date:  2011-02-23       Impact factor: 4.599

8.  Cholesterol activates the Wnt/PCP-YAP signaling in SOAT1-targeted treatment of colon cancer.

Authors:  Huanji Xu; Hongwei Xia; Sheng Zhou; Qiulin Tang; Feng Bi
Journal:  Cell Death Discov       Date:  2021-02-26

Review 9.  Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches.

Authors:  Eduardo Alvarado-Ortiz; Karen Griselda de la Cruz-López; Jared Becerril-Rico; Miguel Angel Sarabia-Sánchez; Elizabeth Ortiz-Sánchez; Alejandro García-Carrancá
Journal:  Front Cell Dev Biol       Date:  2021-02-11

10.  Gain-of-function mutant p53 in cancer progression and therapy.

Authors:  Cen Zhang; Juan Liu; Dandan Xu; Tianliang Zhang; Wenwei Hu; Zhaohui Feng
Journal:  J Mol Cell Biol       Date:  2020-09-01       Impact factor: 6.216

View more
  2 in total

Review 1.  Cholesterol-Lowering Phytochemicals: Targeting the Mevalonate Pathway for Anticancer Interventions.

Authors:  Kagiso Laka; Lilian Makgoo; Zukile Mbita
Journal:  Front Genet       Date:  2022-03-22       Impact factor: 4.599

Review 2.  Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome.

Authors:  Pan Pantziarka; Sarah Blagden
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.